Maja Galić

975 total citations · 1 hit paper
27 papers, 665 citations indexed

About

Maja Galić is a scholar working on Psychiatry and Mental health, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Maja Galić has authored 27 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Psychiatry and Mental health, 5 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Maja Galić's work include Migraine and Headache Studies (13 papers), Trigeminal Neuralgia and Treatments (4 papers) and Sympathectomy and Hyperhidrosis Treatments (3 papers). Maja Galić is often cited by papers focused on Migraine and Headache Studies (13 papers), Trigeminal Neuralgia and Treatments (4 papers) and Sympathectomy and Hyperhidrosis Treatments (3 papers). Maja Galić collaborates with scholars based in United States, Australia and Israel. Maja Galić's co-authors include Peter H. Janssen, Joshua M. Cohen, Richard A. Strugnell, Leanne Sait, Xiaoping Ning, Lindsay Janka, Messoud Ashina, Michel D. Ferrari, Hans‐Christoph Diener and Andrew H. Ahn and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Applied and Environmental Microbiology.

In The Last Decade

Maja Galić

23 papers receiving 643 citations

Hit Papers

Fremanezumab versus placebo for migraine prevention in pa... 2019 2026 2021 2023 2019 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
    2019 274 citations Michel D. Ferrari, Hans‐Christoph Diener et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maja Galić United States 10 357 243 132 124 70 27 665
Manuel Ramos-Kuri Mexico 12 94 0.3× 85 0.3× 141 1.1× 80 0.6× 92 1.3× 20 594
Birgit Keller Germany 15 70 0.2× 155 0.6× 109 0.8× 14 0.1× 91 1.3× 46 784
Edgar Lobos Switzerland 16 96 0.3× 52 0.2× 132 1.0× 113 0.9× 106 1.5× 18 1.1k
Juanjuan Chen China 17 40 0.1× 41 0.2× 220 1.7× 125 1.0× 48 0.7× 55 858
Rami T. El–Sharkawy Canada 10 50 0.1× 24 0.1× 276 2.1× 156 1.3× 224 3.2× 12 933
Jing Peng China 17 51 0.1× 23 0.1× 159 1.2× 62 0.5× 201 2.9× 68 747
Craig Sturgeon United States 9 106 0.3× 33 0.1× 333 2.5× 143 1.2× 346 4.9× 11 1.2k
Paul J. J. Mandigers Netherlands 18 398 1.1× 14 0.1× 159 1.2× 63 0.5× 120 1.7× 87 1.3k
Gloria Serena United States 20 143 0.4× 19 0.1× 443 3.4× 128 1.0× 225 3.2× 29 1.2k

Countries citing papers authored by Maja Galić

Since Specialization
Citations

This map shows the geographic impact of Maja Galić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maja Galić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maja Galić more than expected).

Fields of papers citing papers by Maja Galić

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maja Galić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maja Galić. The network helps show where Maja Galić may publish in the future.

Co-authorship network of co-authors of Maja Galić

This figure shows the co-authorship network connecting the top 25 collaborators of Maja Galić. A scholar is included among the top collaborators of Maja Galić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maja Galić. Maja Galić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lipton, Richard B., et al.. (2025). Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder. JAMA Neurology. 82(6). 560–560. 3 indexed citations
2.
Lipton, Richard B., et al.. (2023). Efficacy of fremanezumab in reducing depression in patients with migraine and major depressive disorder: Results of the UNITE study. Journal of the Neurological Sciences. 455. 121661–121661. 1 indexed citations
3.
4.
MaassenVanDenBrink, Antoinette, Gisela M. Terwindt, Joshua M. Cohen, et al.. (2021). Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study. The Journal of Headache and Pain. 22(1). 152–152. 11 indexed citations
5.
6.
7.
Lipton, Richard B., Joshua M. Cohen, Maja Galić, et al.. (2021). Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache The Journal of Head and Face Pain. 61(4). 662–672. 33 indexed citations
8.
9.
10.
Lipton, Richard B., Joshua M. Cohen, Kristen Bibeau, et al.. (2020). Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study. Headache The Journal of Head and Face Pain. 60(10). 2444–2453. 15 indexed citations
11.
Ferrari, Michel D., Hans‐Christoph Diener, Xiaoping Ning, et al.. (2019). Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet. 394(10203). 1030–1040. 274 indexed citations breakdown →
12.
Galić, Maja, Milan Mesić, Aleksandra Perčin, Ivana Šestak, & Željka Zgorelec. (2018). Sulphur Balance in Agroecosystem. SHILAP Revista de lepidopterología. 3(2). 104–118. 1 indexed citations
13.
Galić, Maja, et al.. (2013). Impact of rotavirus vaccination in Australian children below 5 years of age. Human Vaccines & Immunotherapeutics. 9(8). 1617–1625. 20 indexed citations
14.
Galić, Maja, et al.. (2011). Korištenje i učinkovitost igre u razrednoj nastavi. University of Zagreb University Computing Centre (SRCE). 1(25). 108–121. 3 indexed citations
15.
Galić, Maja, et al.. (2011). THE USE AND EFFICIENCY OF GAMES IN THE CLASS TEACHING. 108–121.
16.
Sait, Leanne, Maja Galić, Jason D. Price, et al.. (2007). Secretory antibodies reduce systemic antibody responses against the gastrointestinal commensal flora. International Immunology. 19(3). 257–265. 60 indexed citations
17.
Tan, Mai Ping, Maria Kaparakis‐Liaskos, Maja Galić, et al.. (2006). Chronic Helicobacter pylori Infection Does Not Significantly Alter the Microbiota of the Murine Stomach. Applied and Environmental Microbiology. 73(3). 1010–1013. 44 indexed citations
18.
Osborne, Catherine A., Maja Galić, Parveen Sangwan, & Peter H. Janssen. (2005). PCR-generated artefact from 16S rRNA gene-specific primers. FEMS Microbiology Letters. 248(2). 183–187. 70 indexed citations
19.
Galić, Maja, et al.. (1990). Salmonella isolation from the organs of slaughter animals and fish meal.. Veterinarski glasnik. 44. 281–285. 1 indexed citations
20.
Galić, Maja, et al.. (1990). The finding of antibodies for Coxiella burnetii in cows having clinical indications of Q-fever.. Acta veterinaria. 40(1). 27–30. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manuel Ramos-Kuri Breakdown of academic impact, for papers by Birgit Keller Breakdown of academic impact, for papers by Edgar Lobos Breakdown of academic impact, for papers by Juanjuan Chen Breakdown of academic impact, for papers by Rami T. El–Sharkawy Breakdown of academic impact, for papers by Jing Peng Breakdown of academic impact, for papers by Craig Sturgeon Breakdown of academic impact, for papers by Paul J. J. Mandigers Breakdown of academic impact, for papers by Gloria Serena
Rankless by CCL
2026